Glucagonlike peptide‐1 receptor agonists versus dipeptidyl peptidase‐4 inhibitors in ischemic strokes with diabetes 2
European Journal of Neurology · 2024
DOI: 10.1111/ene.16329 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Sidsel Hastrup und 4 weiteren Autor:innen. Beteiligte Einrichtung: Danish Stroke Centre, Neurology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Ischemic Stroke, Dipeptidyl-Peptidase IV Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk, Denmark A/S, Novo Nordisk.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background and purpose Cardiovascular outcome trials demonstrate that glucagonlike peptide‐1 receptor agonists (GLP‐1RAs) reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes (T2D), whereas dipeptidyl peptidase‐4 inhibitors (DPP‐4is) have not shown cardiovascular benefits. We compared acute ischemic stroke (AIS) with T2D treated with either a GLP‐1RA or DPP‐4i prior to the index stroke.
Methods
This national cohort study included AIS patients with T2D from 2017 to 2020 in Denmark who were users of a GLP‐1RA or DPP‐4i. To be categorized as a user, we required at least 12 months of exposure and no concurrent treatment with another newer glucose‐lowering medication during the last 3 months prior to the index stroke. GLP‐1RA users were compared to users of DPP‐4i while adjusting for the calendar year of index stroke, age, sex, comorbidity, and socioeconomic factors.
Results
The study included 1567 AIS events with T2D; 593 were users of GLP‐1RA and 974 of DPP‐4i. The absolute risk of a very severe stroke was 2.4% (95% confidence interval [CI] = 1.2–3.7) in GLP‐1RA users and 6.1% (95% CI = 4.6–7.7) in DPP‐4i users. The corresponding adjusted risk ratio (aRR) of GLP‐1RA versus DPP‐4i was 0.49 (95% CI = 0.24–1.00). The aRRs of 30‐day and 365‐day mortality were 0.55 (95% CI = 0.32–0.94) and 0.72 (95% CI = 0.53–0.98), respectively.
Conclusions
The risk of a very severe stroke as well as the 30‐day and 365‐day poststroke mortality rates were lower among the AIS patients with comorbid T2D receiving GLP‐1RA prior to the index stroke compared to those receiving DPP‐4i. Hence, GLP‐1RA may improve stroke outcomes in comparison with DPP‐4i.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Danish Stroke Centre, Neurology, Aarhus University Hospital, Aarhus, Denmark.
- Danish Centre for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
- Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark.
- Steno Diabetes Centre Copenhagen, Herlev, Denmark.
- Department of Endocrinology, Bispebjerg University Hospital, Copenhagen, Denmark.
ORCID-Profile: Sidsel Hastrup
Förderung
- Novo Nordisk, Denmark A/S
- Novo Nordisk
Zitieren
APA
Hastrup, S., Hedegaard, J. N., Andersen, G., Rungby, J., & Johnsen, S. P. (2024). Glucagonlike peptide‐1 receptor agonists versus dipeptidyl peptidase‐4 inhibitors in ischemic strokes with diabetes 2. European Journal of Neurology. https://doi.org/10.1111/ene.16329
Vancouver
Hastrup S, Hedegaard JN, Andersen G, Rungby J, Johnsen SP. Glucagonlike peptide‐1 receptor agonists versus dipeptidyl peptidase‐4 inhibitors in ischemic strokes with diabetes 2. European Journal of Neurology. 2024. doi:10.1111/ene.16329
BibTeX
@article{Hastrup2024,
author = {Hastrup, Sidsel and Hedegaard, Jakob Nebeling and Andersen, Grethe and Rungby, Jørgen and Johnsen, Soren Paaske},
title = {Glucagonlike peptide‐1 receptor agonists versus dipeptidyl peptidase‐4 inhibitors in ischemic strokes with diabetes 2},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16329}
}
EUVIMED